Lucinactant: A novel synthetic surfactant for the treatment of respiratory distress syndrome

Expert Opinion on Investigational Drugs

Volumn 14, Issue 3, 2005, Pages 329-334

  Donn, Steven M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Lucinactant; Prematurity; Respiratory distress syndrome; Surfactant

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; BERACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; PORACTANT;

ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; ARTICLE; ARTIFICIAL VENTILATION; ASTHMA; BRADYCARDIA; CLINICAL TRIAL; DEATH; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HYPOXEMIA; IMMUNOGENICITY; INFECTION; LUNG DYSPLASIA; MECONIUM ASPIRATION; META ANALYSIS; MOUSE; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; RAT; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS; DRUG COMBINATIONS; DRUGS, INVESTIGATIONAL; FATTY ALCOHOLS; HUMANS; INFANT, NEWBORN; PHOSPHATIDYLGLYCEROLS; PROTEINS; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 17144371532     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.3.329     Document Type: Article

References (27)

1. DONN SM, SINHA SK: Respiratory distress syndrome. In: Manual of Neonatal Respiratory Care. SK Sinha, SM Donn (Eds.), Futura Publishing Co., Armonk, NY, USA (2000):260-265.
2. LACAZE-MASMONTEIL T: Exogenous surfactant therapy: newer developments. Semin. Neonatol. (2003) 8:433-440.
3. CURSTEDT T, JORNVALL H, ROBERTSON B et al.: Two hydrophobic, low-molecular mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur. J. Biochem. (1987) 168:255-262.
4. BERNHARD W, MOTTAGHIAN J, GEBERT A, RAU GA, VON DER HARDT H, POETS CF: Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am. J. Respir. Crit. Care Med. (2000) 162:1524-1533.
5. CLARK JC, WERT SE, BACHURSKI CJ et al.: Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc. Natl. Acad. Sci. USA (1995) 92:7794-7798.
6. NOGEE LM, DE MELLO DE, DEHNER LP et al.: Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N. Engl. J. Med. (1993) 328:406-410.
7. MERRITT TA, STRAYER DS, HALLMAN M et al.: Immunologic consequences of exogenous surfactant administration. Semin. Perinatol. (1988) 12:221-230.
8. STRAYER DS, HALLMAN M, MERRITT TA: Immunogenicity of surfactant. II: porcine and bovine surfactants. Clin. Exp. Immunol. (1991) 83:41-46.
9. MOYA F, HOFFMAN D, ZHAO B et al.: Platelet activating factor in surfactant preparations. Lancet (1993) 341:858-860.
10. BRUNI R: Focus on proteins, surfaces. Am. J. Physiol. Lung Cell. Mol. Physiol. (2002) 283:L894-L896.
11. AINSWORTH SB, MILLIGAN DW: Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review. Am. J. Respir. Med. (2002) 1:417-433.
12. COCHRANE CG, REVAK SD: Protein-phospholipid interactions in pulmonary surfactant. The Parker B Francis Lectureship. Chest (1994) 105(Suppl. 3):57S-62S.
13. COCHRANE CG, REVAK SD: Pulmonary surfactant protein B (SP-B): structure-function relationships. Science (1991) 254:566-568.
14. 4. Pediatr. Res. (1996) 39 947-952.
15. ANDERSSON S, KHEITER A, MERRITT TA: Oxidative inactivation of surfactants. Lung (1999) 177:179-189.
16. NUTT M, PATEL N, RAIRKAR M et al.: Comparison of the novel lung surfactant Surfaxin (lucinactant) with currently available commercial products. Pediatr. Res. (2004) 55:514A.
17. REVAK SD, MERRITT TA, COCHRANE CG: In: Investigator Brochure. Surfaxin (lucinactant), Discovery Laboratories, Inc., (2003) (Data on file).
18. DISCOVERY LABORATORIES: In: Investigator Brochure. Surfaxin (lucinactant), Discovery Laboratories, Inc. (2003) (Data on file).
19. ROMERO EJ, MOYA FR, TUVIM MJ, ALCORN JL: Interaction of an artificial surfactant in human pulmonary epithelial cells. Pediatr. Pulmonol. (2005) 39(2):167-177.
20. COCHRANE CG, REVAK SD, MERRITT TA et al.: The efficacy and safety of KL4-Surfactant in preterm infants with respiratory distress syndrome. Am. J. Respir. Crit. Care Med. (1996) 153:404-410.
21. MOYA F, GADZINOWSKI J, BANCALARI E et al.: Superiority of a novel surfactant, Surfaxin (lucinactant) over Exosurf in preventing respiratory distress syndrome in very preterm infants: a pivotal, multinational, randomized trial. Pediatrics (2005) (In Press).
22. SINHA S, LACAZE-MASMONTEIL T, VALLS I SOLER A et al.: Randomized controlled trial of a new generation surfactant, Surfaxin (lucinactant), versus poractant alfa (Curosurf) for the prevention and treatment of respiratory distress syndrome in very preterm infants. Pediatrics (2005) (In Press).
23. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group. Pediatrics (1988) 82:683-691.
24. MOYA F, SINHA S, GADZINOWSKI J et al.: Comparison of all-cause mortality between the novel surfactant Surfaxin (lucinactant) and the animal-derived surfactants Survanta (Beractant) and Curosurf (poractant alfa). Pediatr. Res. (2005) (In Press).
25. SPRAGG RG, LEWIS JF, WALMATH HD et al.: Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N. Engl. J. Med. (2004) 351 884-892.
26. HERTING E, RAUPRICH P, STICHTENOTH G et al.: Resistance of different surfactant preparations to inactivation by meconium. Pediatric Res. (2001) 50:44-49.
27. WISWELL TE, KNIGHT GR, FINER NN et al.: A multicenter, randomized, controlled trial comparing Surfaxin (lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics (2002) 109:1167-1168.